Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/15563650.2021.1914341 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Understanding Cancer Treatment Decision Making Among Cancer Survivors: Weighing Cancer Recurrence Versus Cardiotoxicity.
Psychooncology
January 2025
Integrative Biological and Behavioral Sciences, Division of Extramural Scientific Programs, National Institute on Minority Health and Health Disparities, Rockville, Maryland, USA.
Background: Nearly 20% of US cancer survivors develop cardiovascular disease (CVD) from cardiotoxic cancer treatments. Patients and providers may consider alternative treatments to lower cardiotoxicity risk, but these may be less effective at preventing relapse/recurrence, presenting a difficult tradeoff.
Aims: This study explored survivors' cancer treatment decision-making when weighing this tradeoff.
[Safety and efficacy assessments using human iPS cell-derived cardiomyocytes].
Nihon Yakurigaku Zasshi
January 2025
The delay and loss of drugs are serious problems in Japan. To overcome this issue, it is important to strengthen drug development capabilities. For drug development, the establishment and advancement of non-clinical testing methods are necessary for safe and effective clinical trials.
View Article and Find Full Text PDFA COMPARATIVE STUDY OF CARDIOVASCULAR TOXICITY OF EPIRUBICIN AND DOXORUBICIN IN PATIENTS WITH BREAST CANCER.
Probl Radiac Med Radiobiol
December 2024
National Cancer Institute of the Ministry of Health of Ukraine, 33/43 33/43 Yulia Zdanovska Str., Kyiv, 03022, Ukraine.
Unlabelled: Patients with breast cancer (BC) are at high risk of cardiotoxicity (CT) due to combination of anticancer treatment.Cardio-vascular (СV) complications lead to the delay or discontinuation of anticancer therapy, which significantlyworsens the prognosis. Anthracyclines (AC) are the main drugs included in most anticancer treatment regimens.
View Article and Find Full Text PDFSystemic Toxicity of Recombinant Adeno-Associated Virus Gene Therapy Vectors.
Toxicol Pathol
December 2024
Sanofi, Cambridge, Massachusetts, USA.
Recombinant adeno-associated virus (rAAV) vectors have emerged as a promising tool for gene therapy. However, the systemic administration of rAAV vectors is not without risks, particularly for dose levels >1 × 10 viral genome per kilogram of body weight (vg/kg). rAAV-associated toxicities can variably manifest either acutely or in a delayed manner.
View Article and Find Full Text PDFClinical and Prognostic Characteristics in Childhood Osteosarcoma: A Single-Center Experience in Türkiye.
Turk Arch Pediatr
September 2024
Department of Pediatric Oncology, Ankara University Faculty of Medicine, Ankara, Türkiye.
In our study, we aimed to share the clinical experiences of our center regarding osteosarcoma cases, the most common primary malignant bone tumor in children and adolescents. With approval from the Clinical Research Ethics Committee of our center, the data of 59 pediatric patients who were followed up in our center with the diagnosis of osteosarcoma between 2007 and 2021 were evaluated retrospectively. The mean time between the onset of symptoms and diagnosis was 3 months.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!